Pennathur Arjun, Abbas Ghulam, Schuchert Matthew, Landreneau Rodney J, Luketich James D
The Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Expert Rev Med Devices. 2008 Sep;5(5):613-21. doi: 10.1586/17434440.5.5.613.
Lung cancer is the most common cause of cancer-related mortality in the USA. Surgical resection is the standard treatment for resectable disease; however, a significant percentage of patients with otherwise resectable lung cancer may have other comorbidities, precluding surgical resection. In patients with Stage I non-small-cell lung cancer, conventional external-beam radiotherapy is typically offered as treatment in medically inoperable, high-risk patients with reported 5-year survival rates of 10-30%. An emerging technology in the treatment of lung tumors is radiofrequency ablation, which is a thermal ablative technique and may be applicable in high-risk patients with lung cancer. In this article we will review the principles of radiofrequency ablation, the common devices in use, the experimental background, the results of 'ablate and resect' studies and the clinical experience with radiofrequency ablation in the treatment of lung neoplasm.
肺癌是美国癌症相关死亡的最常见原因。手术切除是可切除疾病的标准治疗方法；然而，相当一部分原本可切除的肺癌患者可能有其他合并症，从而无法进行手术切除。对于I期非小细胞肺癌患者，传统的外照射放疗通常作为医学上无法手术的高危患者的治疗方法，据报道其5年生存率为10%至30%。射频消融是治疗肺部肿瘤的一项新兴技术，它是一种热消融技术，可能适用于高危肺癌患者。在本文中，我们将回顾射频消融的原理、常用设备、实验背景、“消融加切除”研究结果以及射频消融治疗肺部肿瘤的临床经验。
